Cover Image
Market Research Report

Molecular Diagnostics

Published by Global Industry Analysts, Inc. Product code 138654
Published Content info 601 Pages
Delivery time: 1-2 business days
Price
Back to Top
Molecular Diagnostics
Published: August 1, 2016 Content info: 601 Pages
Description

This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousand by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as -

Abbott Laboratories
Abbott Molecular, Inc.
Becton, Dickinson and Company
bioMerieux SA
Cepheid

Table of Contents
Product Code: MCP-1226

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK

  • Global In-Vitro Diagnostics (IVD) Market on a Steady Growth Path
    • Table 1: Global In-Vitro Diagnostics Market by Segment (2015): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Hemostasis (includes corresponding Graph/Chart)
    • Table 2: Global In-Vitro Diagnostics Market by Geographic Region (2015): Percentage Breakdown of Value Sales for the United States, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart)
  • Molecular Diagnostics - A Rapidly Expanding Segment of the IVD Market
  • PCR Technology Leads the MDx Market
  • Current and Future Analysis
  • US and Europe - Leaders in Molecular Diagnostics Adoption
  • Developing Countries Excel in Growth Prospects
  • Major Growth Drivers
  • Key Market Trends in a Nutshell
  • Major Technology Trends
  • Advancements in Molecular Diagnostics - A Boon for the Industry
  • Major Issues and Challenges
  • Market Outlook

2. GROWTH DRIVERS AND MARKET TRENDS

  • Aging Population Drives Molecular Diagnostics Market
  • Global Aging Population Statistics - Opportunity Indicators
    • Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart)
    • Table 4: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
    • Table 5: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
  • Technological Innovations Set to Drive the Market
  • The Role of Molecular Diagnostics in Personalized Medicine
  • Companion Diagnostics Make Way for Personalized Medicine
    • List of Select FDA-Cleared Companion Diagnostic Devices
  • Biomarkers as Companion Diagnostics
  • Rise in Healthcare Spending in Developing Nations Bode Well for Market Growth
    • Table 6: Select Countries with Healthcare Spending as a Percentage of GDP (2014) (includes corresponding Graph/Chart)
  • Proteomics Technologies: Growing in Significance
  • New Developments in Proteomics Technologies
  • New Applications Hold Promising Potential
  • Molecular Diagnostics for Lymphoid Malignancies
  • Next-Generation Sequencing Technologies Keep Up the Momentum
  • Select Commercial NGS Technologies
  • Rising Emphasis on Lab Automation to Augur Well for Market Growth
  • List of Fully Automated and Rapid Molecular Diagnostics
  • Molecular Diagnostics and Intellectual Property
  • Molecular Diagnostics - Moving from Centralization to Decentralization
  • Limited Reimbursements by Third Party Payers - A Stumbling Block

3. APPLICATION AREAS OF MOLECULAR DIAGNOSTICS

  • Infectious Diseases
    • Table 7: World Molecular Diagnostics Market for Infectious Diseases by Test Type: Percentage Share Breakdown for the Year 2015 (includes corresponding Graph/Chart)
  • Bright Prospects Ahead for Molecular Diagnostics for Testing Infectious Diseases
  • Leading Players
  • Key Trends
    • Increasing Incidence of Infectious Diseases Fuels Adoption
    • Table 8: Reported Cases of Major Infections by Select Geographic Region: 2011
    • Rising Incidence of Hospital Acquired Infections Propels Market Growth
    • Table 9: Comparison of Different Parameters for Select C. diff MDx Tests
    • Rising HIV Prevalence Provides Ample Growth Opportunities
    • Table 10: HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart)
    • Table 11: Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart)
    • Table 12: Worldwide AIDS Related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart)
    • Table 13: HIV Prevalence (%) in Adults (15-49 years) by Year: Prevalence Percentage in Adults in 1990, 2000, 2008 & 2014 (includes corresponding Graph/Chart)
    • Infectious Disease Testing - A Major Driver of Molecular Diagnostics Market
      • Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases
    • Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
    • Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
    • HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing Market
      • List of Select HPV Molecular Diagnostic Tests by Company and Technique
  • Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing
    • Major Risk Factors to HPV/Cervical Cancer
    • Table 14: Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart)
    • Table 15: World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart)
    • Table 16: Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in '000s) (includes corresponding Graph/Chart)
  • HPV Testing for Primary Screening Indication Bodes Well for the Market's Growth
    • Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular Diagnostics
      • List of Select Commercially-Available TB Diagnostics
      • An Overview of Select TB Diagnostics under Development
    • Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential...
    • PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
  • Blood Screening
  • Molecular based Tests Ingrain Roots in Blood Donor Screening Segment
  • Cancer Screening & Diagnosis
  • Overview
  • Molecular Tests Lead the Way for Cancer IVD Market Growth
  • Molecular Markers to Enhance Thyroid Cancer Diagnosis
  • Oncology-Based Molecular Diagnostics: The Propitious Segment
    • List of US-FDA Approved Biomarkers for Cancer
    • Table 17: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 18: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart)
    • Table 19: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
  • Growing Popularity of Chemo-Sensitivity Testing of CTCs
  • Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers
  • Other Testing Applications
  • Genetic Disease Testing Applications
    • Overview
    • Pharmacogenomics - Prognosis Based on Genomics
    • Pharmacogenomics Development Augurs Growth of Genetic Testing Market
    • Prospects for Genetic Diagnostics and Testing Grow Brighter
      • List of Select FDA-Cleared Genetic Tests by Disease
    • Genetic Testing - An Indispensible Tool for Cystic Fibrosis
    • Table 20: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
    • Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions
    • Non-Invasive Prenatal Diagnostics - The Way Ahead
    • Nucleic Acid Amplification Methods for Detection of Antimicrobial Resistance
      • PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents
    • Histocompatibility Testing
    • Table 21: Global HLA Testing Market: Revenue Estimates for 2012 through 2016 (in US$ Million) (includes corresponding Graph/Chart)

4. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET

  • An Overview of Competitive Landscape in Molecular Diagnostics
    • Table 22: Global Molecular Diagnostics Market by Leading Player (2015): Percentage Share Breakdown by Value Sales for Roche, Qiagen, Abbott, GenProbe, Siemens, and Others (includes corresponding Graph/Chart)
  • Other Noteworthy Companies and their Competitive Position by Segment
  • Key Players and Their Technologies
    • The Top Tier
    • Mid-Sized and Small Companies
  • Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market
    • Table 23: Price Comparison of Select Fully Automated and Rapid Molecular Diagnostics
  • Qiagen: The Leading Player in the Global HPV MDx Market
    • Comparative Analysis of Select HPV MDx Tests
  • Competitive Dynamics in the C. difficile Testing Market
    • Table 24: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2015): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian, and Others (includes corresponding Graph/Chart)
    • List of Select Molecular C. difficile Test Products
  • Competition in the Blood Screening MDx Market
    • Table 25: Global Blood Screening MDx Market by Leading Players (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Roche, and Others (includes corresponding Graph/Chart)
  • Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market
  • Competitive Landscape in the Global RT-PCR Market
    • Table 26: Leading Players in Global RT-PCR Instruments Market (2012): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players - Thermo Fischer, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart)
    • Select Real-Time PCR Products by Company
  • Competition Heats Up in dPCR Market
    • Table 27: Leading dPCR Systems At a Glance
  • Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market
  • Consolidation Activity Continues to Strengthen Driven by New Entrants
    • Major M&A Transactions in Molecular Diagnostics: 2011-2016
  • Product Marketing - Key to Commercial Success

5. PRODUCT & TECHNOLOGY OVERVIEW

  • Molecular Diagnostics - Definition & Scope
  • Molecular Diagnostics - Impact on Healthcare
  • Utility of Molecular Diagnostic Tests
  • Background of Molecular Diagnostics
  • Major Milestones in the Evolution of Molecular Diagnostics
  • Types of Molecular Diagnostics
  • Conventional Diagnostics Vs. Molecular Diagnostics
  • Unabated Developments in Molecular Diagnostics Technology
  • Signal Amplification Technologies
    • PCR - New Developments
    • Quantitative Real-Time PCR for Molecular Diagnostics
    • Signal Detection and Quantification
    • Quantitative Real-Time RT-PCR Analysis
  • Applications of Quantitative Real-Time PCR Analysis
    • Digital PCR
    • Non-PCR Methods
    • Other Signal Amplification Technologies
  • DNA Probe Based Products
    • Direct Detection of Specific Nucleic Acid Sequences
    • Nucleic Acid Amplification and Detection
    • DNA Sequencing and Gene Detection
    • Arrays of Immobilized Probes (DNA Chips) in Gene Detection
  • RNA Diagnostics
  • Complementary Molecular Diagnostic Technologies
    • Fluorescent In-Situ Hybridization (FISH)
    • DNA Biochips/Microarrays
    • Biosensors
    • Proteomic Technologies for Molecular Diagnostics
    • Nanotechnology for Molecular Diagnostics
  • Technologies on the Anvil
    • Haplotype Analysis - A Distant Possibility
    • Chronic Multi-Gene Defects Now Diagnosable
  • Whole Genome Sequencing - A Boon or a Bane to Genetic Testing?

6. PRODUCT APPROVALS/INTRODUCTIONS

  • Qiagen Introduces New Diagnostic Test for Cervical Cancer
  • GE Showcases Discovery MI and Discovery NM/CT 670 CZT
  • Quest Launches New Tests for Determining Hereditary Cancer
  • Predictive Launches Test for Spine Deformities
  • LabCorp(r) Introduces Epi proColon(r)
  • Agena Rolls Out MassARRAY(r) Dx
  • Rosetta Introduces Three New Diagnostic Offerings
  • bioMerieux Rolls Out GENE-UP(r)
  • Roche Introduces New cobas Range
  • Quest Launches Dako's PD-L1 Complementary Diagnostic Test
  • Quest Introduces Dako's PD-L1 Tests for KEYTRUDA(r)
  • Clarient Rolls Out PD-L1 Test for KEYTRUDA(r)
  • Pathway Unveils CancerIntercept(tm)
  • Cepheid Unveils Xpert(r) Carba-R update
  • Cepheid Launches GeneXpert(r) Omni
  • AlphaImpactRx Introduces BrandImpactDx
  • BioNTech AG Introduces MammaTyper(r)
  • EKF Showcases Molecular Diagnostics Products Series
  • Microbix Unveils New Molecular Diagnostics Range
  • Roche Introduces cobas(r) Liat System
  • Quest Unveils BRCAvantage Plus
  • Cepheid Rolls Out Xpert(r) TV
  • OpGen Introduces Acuitas(tm) MDRO Gene Test
  • DaVita Introduces Molecular Diagnostic Testing
  • Grifols Obtains CE-Marking for ID CORE XT Molecular Diagnostic Kit
  • QIAGEN Rolls Out careHPV(tm) Test in India
  • QIAGEN Gets PMA Approval from the US FDA for artus(r) CMV RGQ MDx Kit
  • Alere Obtains FDA Approval for Alere(tm) i Influenza A and B Test
  • Qiagen Obtains Approval from the US Health Regulators for Gene-Testing Kit
  • Immucor Obtains the US FDA Approval for PreciseType HEA Test
  • Biocartis Introduces Idylla(tm)
  • Roche Introduces cobas 6800/8800 Systems
  • Roche Unveils CINtec PLUS*
  • Roche Rolls Out cobas(r) HIV-1 and cobas HCV assays

7. RECENT INDUSTRY ACTIVITY

  • Bio-Techne to Acquire Advanced Cell Diagnostics
  • Myriad Acquires Sividon Diagnostics
  • Siemens Acquires Neo New Oncology
  • Luminex to Acquire Nanosphere
  • DiaSorin Completes Acquisition of Focus Diagnostics
  • Avant Acquires Amarantus Diagnostics
  • HTG to Collaborate With Bristol-Myers Squibb
  • Miroculus to Acquire Kapplex
  • Cepheid's Xpert(r) MRSA NxG Gets European Approval
  • SpeeDx Collaborates with Goffin Molecular
  • FDA Approves BD's Totalys(tm)
  • CE Mark Approves BioFire Diagnostics' FilmArray(r)
  • Thermo Fisher Acquires Affymetrix
  • Qiagen Collaborates with Mirati
  • BioGenex to Commence Operations from India Center
  • Illumina Collaborates with investors to Launch GRAIL
  • Thermo Fisher Collaborates with Karolinska Institute
  • CE Mark Approves Aptima(r) HCV Quant Dx Assay by Hologic
  • FDA Approves BioFire Diagnostics' FilmArray(r)
  • ERBA Acquires Lumora
  • Seegene Collaborates with BD Life Sciences
  • MDxHealth to Acquire NovioGendix
  • Quest's Simplexa HSV 1 & 2 Test Gets FDA 510(k) Approval
  • Burning Rock Partners with Illumina
  • GE's Low Dose CT Screening Approved by FDA
  • Roche to Acquire GeneWEAVE BioSciences
  • Cancer Genetics Acquires Response Genetics, Inc
  • OpGen Acquires AdvanDx
  • Hitachi Collaborates with QIAGEN
  • OPKO Takes Over Bio-Reference Laboratories
  • Sysmex Signs Agreement with IndivuTest
  • CE Mark Approves Xpert(r) HIV-1 Qual by Cepheid and FIND
  • Xpert(r) HCV Viral Load by Cepheid gets CE Mark Approval
  • Rosetta Acquires CynoGen
  • Microbix Signs Agreement with Microbiologics
  • Cepheid Receives Emergency Use Authorization by FDA for Ebola Test
  • Novigenix Acquires Colox(r)
  • Roche Takes Over Signature Diagnostics
  • CE Mark Approves QIAGEN's Circulating Tumor DNA Test
  • Amarantus Completes Acquisition of DioGenix
  • Aegis Acquires Diagnovus
  • Empire Announces Acquisition of ID Labs
  • OncoGxSelect(tm) Receives NJDH Approval
  • Roche Takes Over Ariosa
  • FDA Approves Xpert(r) Norovirus by Cepheid
  • Cepheid's Xpert(r) Flu/RSV XC Gets FDA Approval
  • Roche's cobas(r) Strep A Test Receives 510(k) Clearance
  • PDI Takes Over RedPath
  • Veracyte Acquires Allegro Diagnostics
  • GTCR Takes Over XIFIN
  • QIAGEN to Collaborate with AstraZeneca
  • BD Collaborates with MD Anderson Cancer Center
  • Roche Acquires IQuum
  • Myriad to Acquire Crescendo Bioscience
  • Co-Diagnostics Unveils Co-Dx(tm)
  • bioMerieux Acquires BioFire Diagnostics
  • Thermo Fisher Scientific Acquires Life Technologies
  • Myriad Genetics Takes Over Crescendo Bioscience
  • AUT University Collaborates with Roche Diagnostics
  • Corgenix Medical Obtains NIH Grant to Advance Development of Ebola Rapid Diagnostic Test Kit
  • Cepheid Collaborates with AstraZeneca, Cubist Pharmaceuticals and GSK
  • B Braun US and CeGaT Join Forces to Establish B Braun CeGaT
  • Provista Diagnostics Expands Exclusive License Agreement for Certain Biomarker and Autoantibody Technologies
  • Veracyte and Fleury Partner to Offer the Afirma(r) Gene Expression Classifier
  • Integrated Diagnostics Attracts Financing for Xpresys Lung Molecular Diagnostic Blood Test
  • MDxHealth Enters into Agreement with Galaxy Health
  • QIAGEN Acquires Exclusive Worldwide License to CALR Biomarker
  • Zyomyx Obtains $7.5 Million from UNITAID to Launch MyT4(tm) POC CD4 Test
  • Human Longevity Inc. Commences its Operations
  • Roche Takes Over IQuum
  • Myriad Genetics and Sividon Diagnostics Ink Exclusive Co-Marketing Agreement

8. FOCUS ON SELECT PLAYERS

  • Abbott Laboratories (US)
  • Abbott Molecular, Inc. (US)
  • Becton, Dickinson and Company (US)
  • bioMerieux SA (France)
  • Cepheid (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • RMD's Product Portfolio by Segment
  • RMD's Major Test Offerings by Application
  • GE Healthcare (US)
  • Grifols International, S.A. (Spain)
  • Hologic, Inc. (US)
  • QIAGEN N.V. (The Netherlands)
  • Quest Diagnostics, Inc. (US)
  • Siemens Healthcare GmBH (Germany)
  • Tecan Group Ltd. (Switzerland)
  • The ELITechGroup SAS (France)
  • Thermo Fisher Scientific (US)

9. GLOBAL MARKET PERSPECTIVE

    • Table 28: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 30: World 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
  • Molecular Diagnostics Market by Application
    • Table 31: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 32: World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 33: World 14-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 34: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 35: World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 36: World 14-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 37: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 38: World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 39: World 14-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 40: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 42: World 14-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • US Molecular Diagnostics Market Maintain its Growth Momentum
      • Competitive Landscape
    • qPCR and dPCR Instrumentation in the US: An Overview
    • Ageing Demographics: Major Driving Factor
    • Table 43: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Increasing Incidence of Chronic Diseases Drives Focus onto Molecular Diagnostics
    • US Individualized Medicine Market to Witness Significant Growth
    • Companion Diagnostics Market in the US
      • List of Select FDA-Cleared Companion Diagnostics
    • Burgeoning Potential for Genetic Testing
      • Direct-to-Consumer Testing - A Growing Market
    • Epidemic Proportion of Cancer in the US - Key Driver for Cancer Genetic Testing
    • Table 44: New Cancer Cases in the US by Gender and Affected Site: 2014 (includes corresponding Graph/Chart)
    • Table 45: Incidence of Cancer for All Body Sites by Gender & Age Group in the US (2013): New Cancer Cases for Males & Females for the Age Groups Under 45 years; 45 years and Above; Under 65 years; 65 years and Above (includes corresponding Graph/Chart)
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
      • List of FDA-Cleared CF MDx Tests
    • Molecular Diagnostics Tests Gaining Share in STD Testing Domain
    • HPV Testing Market - A Review
    • Table 46: Prevalence of HPV in the US by Age (includes corresponding Graph/Chart)
    • Table 47: Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart)
    • Table 48: Number of New Cervical Cancer Cases by US State (2015)
      • Competitive Landscape
    • Table 49: Leading Players in the US HPV Testing Market (2013): Percentage Share Breakdown of Revenues for Hologic, QIAGEN, and Others (includes corresponding Graph/Chart)
      • List of FDA Approved HPV MDx Tests
    • Regulatory Environment
      • FDA Regulations
      • Clinical Laboratory Improvement Amendments (CLIA)
    • Table 50: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Laboratories by Certificate Type (includes corresponding Graph/Chart)
    • Table 51: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Labs by Lab Type (includes corresponding Graph/Chart)
      • Genetic Testing
      • FDA to Implement Strict Measures for Cervical Cancer Screening Tests
      • Limited Reimbursements - A Major Hindrance
      • New MoPath Codes for Reimbursement for Molecular Diagnostics Tests
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 52: The US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 53: The US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 54: The US 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • Cancer Incidence in Canada: Opportunity Indicator
    • Table 55: New Cancer Cases in Canada by Gender and Affected Site: 2014 (includes corresponding Graph/Chart)
    • Table 56: New Cancer Cases in Canada by Province: 2014 (includes corresponding Graph/Chart)
    • Table 57: New Cancer Cases in Canada by Age Group: 2014 (includes corresponding Graph/Chart)
    • Product Approval
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 58: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 59: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 60: Canadian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Demographics Drive Market Growth
    • Table 61: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 62: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 63: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 64: Japanese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Insight into Molecular Diagnostics Markets in Europe
    • Table 65: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)
    • Increasing Testing Needs of the Elderly: Business Case for Molecular Diagnostics
    • Table 66: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
    • PCR Reagents in Europe: An Overview
    • Automated Systems Gain Preeminence
    • Oncology-based Molecular Diagnostics Holds Immense Potential
    • Table 67: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart)
    • European Personalized Medicine Market to Exhibit Robust Growth
    • HPV Testing in Europe: An Overview
    • Table 68: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart)
    • Table 69: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart)
    • Table 70: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart)
    • Table 71: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart)
      • List of Select CE-Marked HPV Molecular Diagnostic Tests
    • Cervical Cancer Screening in Europe - A Review
    • Table 72: Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart)
    • Table 73: Cervical Cancer Incidence and Mortality in European Countries (2012)
    • Table 74: Prevalence of Cervical Cancer in European Countries (2012)
    • Table 75: European HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 76: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 77: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 78: European 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 79: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 80: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 81: European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launch
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 82: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 83: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 84: French 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launches
    • Strategic Corporate Developments
    • Siemens AG - A Key Player
  • B. Market Analytics
    • Table 85: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 86: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 87: German 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 88: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 89: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 90: Italian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • SMIP for Pharmacogenomic Testing
  • B. Market Analytics
    • Table 91: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 92: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 93: The UK 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current and Future Analysis
    • Spain - Poised to become a Reckoning Force in Personalized Medicines
    • Strategic Corporate Development
    • Grifols International, S.A. - A Key Player
  • B. Market Analytics
    • Table 94: Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 95: Spanish Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 96: Spanish 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 97: Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 98: Russian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 99: Russian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 100: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 101: Rest of European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 102: Rest of European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Healthcare Spending in Asia-Pacific: On the Rise
    • In-vitro Diagnostics Market: India & China Offer Significant Growth Opportunities
    • Table 103: China and India Leads Global Population (July 2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart)
    • Table 104: Age-wise Breakup of China and India's Population Vis-a-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart)
    • Molecular Diagnostics Testing Opens New World of Possibilities
    • Recent Advancements in Molecular Diagnostics Market: A Quick Review
      • Novel Genetic Testing Methods
      • Development of Personalized Healthcare Approaches
      • Molecular Painting for Genetic Diagnosis of Diseases
      • New Technique to Detect H1N1 Virus
  • B. Market Analytics
    • Table 105: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 106: Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 107: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 108: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 109: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 110: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current and Future Analysis
    • In-Vitro Diagnostics Market on the Growth Curve
    • HPV Testing in China: An Overview
    • Government Support Drives Personalized Medicine Market in China
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 111: Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 112: Chinese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 113: Chinese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

5b. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • A Focus on the Indian Molecular Diagnostics Market
      • Molecular Diagnostic Market in India to Witness Significant Growth
      • Growth Drivers in a Nut Shell
      • Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
      • Indian Scientific Research towards Functional Genomics and Proteomics
      • Automation - The Emerging Trend in IVD Industry
      • Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
      • HPV Testing Market: An Overview
    • Table 114: HPV in India - Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart)
    • Product Launche/Approval
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 115: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 116: Rest of Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 117: Rest of Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Current and Future Analysis
    • Brazilian IVD Market on the Rise
  • B. Market Analytics
    • Table 118: Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 119: Latin American Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 120: Latin American 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launch
  • B. Market Analytics
    • Table 121: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 122: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 123: Rest of World 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Back to Top